Stay updated on GARNET: Anti-PD-1 Antibody Clinical Trial
Sign up to get notified when there's something new on the GARNET: Anti-PD-1 Antibody Clinical Trial page.
Latest updates to the GARNET: Anti-PD-1 Antibody Clinical Trial page
- Check22 days agoChange DetectedThe web page has undergone significant content changes, including the removal of detailed descriptions of a Phase 1 study evaluating the anti-PD-1 antibody dostarlimab and the addition of new identifiers and a revision number.SummaryDifference28%
- Check29 days agoChange DetectedThe page has been updated to reflect the latest version as v2.14.4, replacing the previous version v2.14.2. The estimated last update posted has been removed.SummaryDifference0.0%
- Check66 days agoChange DetectedThe web page has been updated to reflect a new total of 130 study locations, with several principal investigators added, including Charles A. Leath, III and Michael S. Gordon. Additionally, several previously listed locations have been withdrawn, including sites in Phoenix, Atlanta, and Buenos Aires.SummaryDifference15%
- Check120 days agoChange DetectedThe website has updated its clinical trials information, adding new contact details and a revision to version 2.14.0, while removing the previous version 2.13.3 and its associated contact information.SummaryDifference45%
- Check142 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check149 days agoChange DetectedThe website has been updated from version 2.13.0 to 2.13.2, indicating new features or improvements.SummaryDifference0.0%
Stay in the know with updates to GARNET: Anti-PD-1 Antibody Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GARNET: Anti-PD-1 Antibody Clinical Trial page.